<code id='ED55614F51'></code><style id='ED55614F51'></style>
    • <acronym id='ED55614F51'></acronym>
      <center id='ED55614F51'><center id='ED55614F51'><tfoot id='ED55614F51'></tfoot></center><abbr id='ED55614F51'><dir id='ED55614F51'><tfoot id='ED55614F51'></tfoot><noframes id='ED55614F51'>

    • <optgroup id='ED55614F51'><strike id='ED55614F51'><sup id='ED55614F51'></sup></strike><code id='ED55614F51'></code></optgroup>
        1. <b id='ED55614F51'><label id='ED55614F51'><select id='ED55614F51'><dt id='ED55614F51'><span id='ED55614F51'></span></dt></select></label></b><u id='ED55614F51'></u>
          <i id='ED55614F51'><strike id='ED55614F51'><tt id='ED55614F51'><pre id='ED55614F51'></pre></tt></strike></i>

          knowledge

          knowledge

          author:Wikipedia    Page View:3574
          Two business miniatures talk to each other on coin stacks that are sandwiched by a syringe and a stethoscope — coverage from STAT
          Adobe

          For all the flak they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers.

          But don’t take their numbers as gospel, experts warned.

          advertisement

          “It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Economics. “If one segment of your vertically integrated organization is not publishing any financial data, it’s a good place to hide stuff.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Tori Bowie and the unacceptable rates of Black maternal death
          Tori Bowie and the unacceptable rates of Black maternal death

          AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

          read more
          Longer MASH drug regimen improved liver, Akero study finds
          Longer MASH drug regimen improved liver, Akero study finds

          AdobeAkeroTherapeuticssaidMondaythatextendingtreatmentwithitsexperimentaldrugfortheliverdiseaseknown

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Families look for replacement for GSK asthma drug Flovent

          BostonGlobeAcommonlyprescribedmedicationforchildren’sasthmaisdisappearingfrompharmacists’shelves,for